Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ernst Forjan"'
Autor:
Ruth M. Urbantat, Valentin Popper, Elisabeth Menschel, Michael Pfeilstöcker, Ernst Forjan, Alexander Nader, Catherine R. Sieghart, Felix Keil, Elisabeth Koller
Publikováno v:
Clinical Case Reports, Vol 9, Iss 4, Pp 1933-1936 (2021)
Abstract CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized
Externí odkaz:
https://doaj.org/article/4efcefba4b1242baaf7036d055ec3825
Autor:
Wolfgang Schimetta, Ernst Forjan, Reinhard Ruckser, Maria Theresa Krauth, Juergen Thiele, Heinz Gisslinger, Dominik Wolf, Bettina Gisslinger, Sonja Heibl, Veronika Buxhofer-Ausch, Siegfried Sormann
Publikováno v:
European Journal of Haematology
Objectives Cell counts have a significant impact on the complex mechanism of thrombosis in patients with essential thrombocythemia (ET). We recently demonstrated a considerable impact of white blood cell (WBC) counts on thrombotic risk in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b12fa3e029d9c74b77fad16ced02dce4
https://doi.org/10.1111/ejh.13516
https://doi.org/10.1111/ejh.13516
Autor:
Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, Georgi Mihaylov, Hans Carl Hasselbalch, Lydia Roy, Vera Yablokova, Olga Cerna, Aleksander Skotnicki, Richard Greil, Jiri Schwarz, Vera Stoeva, Lylia Sivcheva, Zvenyslava Masliak, Halyna Pylypenko, Antonia Hatalova, Delia Dima, Jose Miguel Torregrosa-Diaz, Elena Volodicheva, Jean-Jacques Kiladjian, S V Klymenko, Carlos Besses Raebel, Polina Kaplan, Irina Sokolova, Horia Bumbea, Miklos Egyed, Nicoleta Berbec, Barbara Grohmann-Izay, Alexander Myasnikov, Petr Dulicek, Tamila Lysa, Dominik Wolf, Andrei Cucuianu, Christoph Klade, Mihaela Lazaroiu, Maria Soroka-Wojtaszko, Tamás Masszi, Ernst Forjan, Liana Gercheva-Kyuchukova, Franz Bauer, Dorota Krochmalczyk, Árpád Illés, Mikulas Hrubisko, Jolanta Starzak-Gwozdz, Viktor Rossiev
Publikováno v:
The Lancet Haematology. 7:e196-e208
Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. Methods PRO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef767894c3f5dbd8084e8e09eb738e2f
https://doi.org/10.1016/s2352-3026(19)30236-4
https://doi.org/10.1016/s2352-3026(19)30236-4
Autor:
Karin Stiasny, Ernst Forjan, Felix Keil, Elisabeth Zwettler, Andreas Krauter, Johann Bartko, Lukas Weseslindtner, Nazanin Sédille-Mostafaie, Sonja Zehetmayer, Andrea Schloegl
Publikováno v:
Journal of Clinical Medicine
Volume 10
Issue 9
Journal of Clinical Medicine, Vol 10, Iss 1909, p 1909 (2021)
Volume 10
Issue 9
Journal of Clinical Medicine, Vol 10, Iss 1909, p 1909 (2021)
Despite being located close to the European epicenter of the COVID-19 pandemic in Italy, Austria has managed to control the first wave. In Austria, the largest health insurance fund covers 7 million people and has 12,000 employees, including 3700 hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6463ed937c6ff10b0bb003247d25cecd
Autor:
Caroline Sieghart, Alexander Nader, Ernst Forjan, Michael Pfeilstoecker, Ruth-Maria Urbantat, Elisabeth Menschel, Elisabeth Koller, Felix Keil, Valentin Popper
CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ce582210819e8f8544ac058e4bfa99f
https://doi.org/10.22541/au.159610144.47192330
https://doi.org/10.22541/au.159610144.47192330
Autor:
Ella Willenbacher, Pavla Kadlecová, Ernst Forjan, Michael Zoerer, Victoria Empson, Josef Thaler, Sonja Burgstaller, Thomas Melchardt, Margarete Stampfl-Mattersberger, Martin Schalling, Veronika Buxhofer-Ausch, Barbara Grohmann-Izay, Richard Greil, Maria-Theresa Krauth, Alexander Egle, Christoph Klade, Heinz Gisslinger, Bettina Gisslinger, Robert Kralovics, Dominik Wolf
Publikováno v:
Blood. 132:3030-3030
Background: Ropeginterferon alfa-2b (Ropeg) is a novel long-acting monopegylated IFN-alpha-2b. Due to reduced dosing frequencies, better tolerability and improved compliance, Ropeg may be a favorable treatment option for long-term therapy in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dade708fcec1a91e695c554c1199ad9d
https://doi.org/10.1182/blood-2018-99-118584
https://doi.org/10.1182/blood-2018-99-118584